22.91
+1.63(+7.66%)
Currency In USD
| Previous Close | 21.28 |
| Open | 21.31 |
| Day High | 23.19 |
| Day Low | 20.81 |
| 52-Week High | 35.25 |
| 52-Week Low | 13.53 |
| Volume | 3.24M |
| Average Volume | 2.56M |
| Market Cap | 2.32B |
| PE | -5.09 |
| EPS | -4.5 |
| Moving Average 50 Days | 19.17 |
| Moving Average 200 Days | 21.72 |
| Change | 1.63 |
If you invested $1000 in Beam Therapeutics Inc. (BEAM) since IPO date, it would be worth $1,221.87 as of September 17, 2025 at a share price of $22.91. Whereas If you bought $1000 worth of Beam Therapeutics Inc. (BEAM) shares 3 years ago, it would be worth $425.92 as of September 17, 2025 at a share price of $22.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
GlobeNewswire Inc.
Aug 25, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at th
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
GlobeNewswire Inc.
Aug 14, 2025 11:00 AM GMT
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administrati
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
GlobeNewswire Inc.
Jun 13, 2025 11:00 AM GMT
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of On